BREAKING NEWS: On September 15, 2025, the U.S. House of Representatives passed H.R. 5100, a bipartisan bill that provides a one-year extension for the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. The extension shifts the expiration date from September 30, 2025, to September 30, 2026. The US Senate now must act to get a reauthorization bill on the President's desk. The SBIR/STTR programs fuel innovation, empower small businesses, strengthen the economy, and deliver technologies that improve lives and protect the nation. Here in Arizona, these programs are a significant source of funding that helps discoveries progress to become life saving and life changing products and services. SBIR/STTR must be reauthorized by Congress by September 30, 2025. Now is the time to let our elected leaders know why Arizonans depend on these programs.
Author Archive: AZBio
Reference Medicine: Fast-Tracking Innovation in Cancer Diagnostics
Each year, AZBio recognizes the select few companies that have achieved outstanding and are accelerating innovation. Reference Medicine is one of these Fast Lane companies. Continue reading
Crescent Edge Managing Partner Nannon Roosa Appointed Chair of BIOSA Board to Lead Southern Arizona Bioscience Growth
The Bioindustry Organization of Southern Arizona (BIOSA) has appointed Nannon Roosa, PMP, CPA, FACMPE, Managing Partner of Crescent Edge LLC, as Chair of its Board of Directors.Continue reading
AZBio Awards to honor two U of A faculty members, startup company
Melissa Herbst-Kralovetz, LifeSpan Digital Health and Dr. Eric Reiman are being recognized by the Arizona Bioindustry Association.
Continue reading
Executive Order seeks to ensure Arizonans who want COVID vaccine can get one
Phoenix, AZ – Today, Governor Katie Hobbs signed an Executive Order expanding access to COVID vaccines in Arizona. This action seeks to protect the health and safety of Arizona families ahead of respiratory disease season, and to reduce the strain on Arizona’s hospital system and health care workers.Continue reading
XLR8 PBC Introduces Fall 2025 Cohort
New Arizona’s Bioscience Roadmap: How the state becomes a nationally recognized bioscience hub
The Flinn Foundation releases a new Arizona’s Bioscience Roadmap to guide industry discovery, innovation, and economic growth for the next five years. The new plan builds on Arizona’s talent base, world-class research, and entrepreneurial spirit to improve the economy as well as Arizonans’ health and quality of life. Developed by SRI International of Menlo Park, Calif., the Roadmap launches at stakeholder events statewide and online the week of Sept. 8, 2025.Continue reading
Flinn Foundation Translational Seed Grants Program – Apply by Oct. 31 2025
It’s that time of the year again. The Flinn Foundation is seeking applicants for the 11th cohort of its Translational Seed Grants Program! The RFP opened Sept. 3, 2025 and closes on Friday, Oct. 31.Continue reading
Picard Medical, Inc. Announces Pricing of $17 Million Initial Public Offering
TUCSON, ARIZONA, August 28, 2025 — Picard Medical, Inc. (“Picard” or the “Company”), a medical technology company that manufactures and sells the only total artificial heart (the “SynCardia Total Artificial Heart”, or “STAH”) approved by the U.S. Food and Drug Administration (“FDA”), and Health Canada, today announced the pricing of its initial public offering (the “Offering”). The Offering consists of 4,250,000 shares of common stock priced at a public offering price of $4.00 per share, for total gross proceeds of $17 million, before deducting underwriting discounts and offering expenses. The shares of common stock have been approved for listing on the NYSE American, LLC and are expected to commence trading on August 29, 2025, under the ticker symbol “PMI.”Continue reading
GPEC Board of Directors names Christine Mackay as President & CEO
Over 11 years with the City of Phoenix, Mackay led the creation of more than $190 billion in capital investment and 100,000 new jobsContinue reading